Age: 69.0
Sex: F
Vaccine: COVID19
Symptoms: Blood test, Hyperaesthesia, Rash, Rash erythematous, Rash pruritic
Clinical narrative: skin is still extremely sensitive; Developed rash to injection site of the vaccine (unknown arm); Bad skin rash that was red, itchy and painful; Bad skin rash that was red, itchy and painful; Bad skin rash that was red, itchy and painful; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP) from medical information team for a Pfizer sponsored program (002191). The reporter is the patient.  A 69 year-old female patient received bnt162b2 (BNT162B2), administered in arm, administration date 27Feb2021 (Lot number: EN6203, Expiration Date: Jun2030) as dose 2, single and administered in arm left, administration date 04Sep2021 (Lot number: FC3181) as dose 3 (booster), single for covid-19 immunisation. Relevant medical history included: "Allergy to shell fish" (ongoing), notes: Verbatim: Allergy to shell fish, Stated that it was an unknown date before the vaccine.; "Allergy to wool" (ongoing), notes: Stated that she was diagnosed 25-30 years ago.; "Chronic Lymphocytic Leukaemia" (unspecified if ongoing); "skin is still extremely sensitive" (ongoing), notes: sensitive since an unknown date before the vaccine. There were no concomitant medications. Vaccination history included: Bnt162b2 (Lot no: EL9264   , Anatomical location: arm, Dose no: 1), administration date: 06Feb2021, when the patient was 69 years old, for COVID-19 immunization. The following information was reported: RASH ERYTHEMATOUS (medically significant), RASH PRURITIC (medically significant), RASH (medically significant) all with onset 2021, outcome "recovered" (Sep2021) and all described as "Bad skin rash that was red, itchy and painful"; HYPERAESTHESIA (non-serious), outcome "not recovered", described as "skin is still extremely sensitive"; VACCINATION SITE RASH (non-serious) with onset Mar2021, outcome "recovered" (14Mar2021), described as "Developed rash to injection site of the vaccine (unknown arm)". The patient underwent the following laboratory tests and procedures: blood test: no response; no response. Therapeutic measures were taken as a result of rash erythematous, rash pruritic, rash.  Clinical course: The caller states that she had received 3 doses of the Pfizer COVID-19 vaccine, 2 doses in Feb2021 and then another dose in Sep2021, and she had not developed any antibodies after any of these doses. The caller also reports developing a bad skin rash that was red, itchy and painful after the second and third dose of the Pfizer COVID-19 vaccine. She states after the second dose the rash lasted about 9 or 10 days but she did not take any medication or seek treatment for the rash. She reported that after her third dose she developed the same type of rash and she did treat that rash with Benadryl. Clarified that she had leukaemia before the vaccine. Stated that she did not know if this was her time completing a report but she thinks so. Stated that her skin was extremely sensitive since an unknown date before the vaccine. Stated that her skin was still extremely sensitive. Event details were reported as follows, stated that they did two blood tests on her after the second and third dose and they both showed no response. Stated that the doctor has not done tests since her third dose. Did not recall any dates of the tests. Stated that the skin rash was after the second dose then later stated that it was after the first dose and then later clarified that it was after the second dose. Clarified that the skin rash after the second dose was to the injection site of the vaccine which was an unknown arm. Stated that she developed a skin rash after the third dose on 05Sep2021 or 06Sep2021. Clarified that the skin rash after the third dose was to the left arm. Stated that it resolved 10 days later. Recovered completely. Regarding treatment, it was stated that she put cortisone cream on the skin rash after the second dose. Stated that she took Benadryl and used cortisone cream for the skin rash after the third dose. Description of complaint were reported as follows, Pfizer Covid 19 vaccine: Stated that she had not developed any antibodies after any of the doses. Stated that they did two blood tests on her after the second and third dose and they both showed no response. Caller asks if the Pfizer COVID-19 vaccine booster dose was the same ingredients and dose as the primary series. Caller asks if it is okay to get a Moderna COVID vaccine for a booster dose if someone has gotten the Pfizer COVID-19 vaccine as their primary dose. Caller states that she had heard people who have not developed antibodies from the Pfizer COVID-19 vaccine primary series should get a booster with the Moderna COVID-19 vaccine. She would like to know if there is any supporting information